Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR(−)/HER2(+) breast cancers

HER2-positive (HER2(+)) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory network analysis, we identified STAT3 as a critically activated master regulator...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Genes Dev
Main Authors: Rodriguez-Barrueco, Ruth, Yu, Jiyang, Saucedo-Cuevas, Laura P., Olivan, Mireia, Llobet-Navas, David, Putcha, Preeti, Castro, Veronica, Murga-Penas, Eva M., Collazo-Lorduy, Ana, Castillo-Martin, Mireia, Alvarez, Mariano, Cordon-Cardo, Carlos, Kalinsky, Kevin, Maurer, Matthew, Califano, Andrea, Silva, Jose M.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory Press 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4536311/
https://ncbi.nlm.nih.gov/pubmed/26227964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.262642.115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados